𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biomarker Modulations in Children With Neuroblastoma Following Treatment With 131I-mIBG

✍ Scribed by Imber, B.S.; Olow, A.; Karski, E.E.; Allen, I.E.; DuBois, S.G.; Haas-Kogan, D.A.

Book ID
127060497
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
75 KB
Volume
90
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of neuroblastoma with131I-MIBG
Treatment of neuroblastoma with131I-MIBG: Dosimetric problems and perspectives
✍ Beierwaltes, William H. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 402 KB

Between 7/3/80 and 5/7/86 we gave 32 of our neuroblastoma patients 62 diagnostic doses of metaiodobenzylguanidine (MIBG) and 12 patients 20 treatment doses. Our conclusion from our diagnostic dose studies is that MIBG should be used for staging the extent of neuroblastoma before therapy is started,

Second malignancies in children with neu
Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine
✍ Alberto Garaventa; Claudio Gambini; Giampiero Villavecchia; Andrea Di Cataldo; L πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 127 KB

## Abstract ## BACKGROUND ^131^I‐metaiodobenzylguanidine (^131^I‐MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with modera